Moreover, one recently published meta-analysis showed that, compared with other surveillance tools (i.e., CEA, CT, and PET), ctDNA was most often positively correlated with CRC recurrence [46], indicating that the use of ctDNA may serve as a precise tool for monitoring cancer relapse during CRC follow-up. This evidence concerns the gene CEACAM5 and cancer.